KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Q3 2025 value amounting to $91.3 million.

  • CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) rose 712.2% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year increase of 712.2%. This contributed to the annual value of $84.4 million for FY2024, which is 648.59% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Shares Outstanding (Diluted Average) of $91.3 million as of Q3 2025, which was up 712.2% from $87.1 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) peaked at $91.3 million during Q3 2025, and registered a low of $75.0 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) had a median value of $79.3 million in 2023 and averaged $81.4 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) surged by 2326.71% in 2021 and then skyrocketed by 178.49% in 2023.
  • CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) (Quarter) stood at $75.0 million in 2021, then rose by 3.65% to $77.7 million in 2022, then grew by 1.9% to $79.2 million in 2023, then rose by 6.49% to $84.4 million in 2024, then grew by 8.23% to $91.3 million in 2025.
  • Its last three reported values are $91.3 million in Q3 2025, $87.1 million for Q2 2025, and $85.9 million during Q1 2025.